Immatics TCER - Molecules

Immatics’ TCER® scaffold is the result of a campaign to engineer and evaluate various molecular scaffolds incorporating binding domains derived from affinity and stability enhanced TCRs and from T cell recruiting antibodies, respectively. The TCER® architecture, in Immatics’ in vitro testing, proved to be superior to other tested scaffolds with respect to preclinical efficacy, stability and physio-chemical properties, so called “developability”. TCER® molecules can readily be expressed in CHO-cells with titers comparable to antibody-based biologics. The TCER® protein can be purified using common chromatographic techniques and size-exclusion-chromatography, facilitating the cGMP-compliant manufacturing in established plants.

The manufacturing development phase of IMA401 TCER® is ongoing and includes cell line development, upstream and downstream process development, GMP production, fill and finish, release testing, storage and stability testing.